Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
NY's attorney general alleges that a formulation switch is an attempt to create monopoly.
Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
The Windy City seeks $9.5 million in damages in a lawsuit that accuses manufacturers of misleading consumers.
Orange and Santa Clara counties are suing painkiller makers like Purdue and Endo, a suit akin to deceptive ad cases launched against the tobacco industry.
Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.
The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.
The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.
The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.
The drugmaker may be able to settle around 3,800 cases for $100 million.
The Star-Ledger reports that the company's Ethicon unit destroyed development documents about its vaginal mesh products as a matter of course. The company's West Virginia legal scuffle over the product begins Monday.
The complaint centers around iron-control drug Exjade.
The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.
The company is paying $2.5 billion over its DePuy hip replacements and $11 million in a lawsuit over its seizure drug Topamax.
The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.
Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.
Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review
The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.
The first prescription non-hormonal treatment offers relief for women who do not want to tangle with hormone-replacement therapy.
The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.
It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.
Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.
Endo gets a new president, Allergan settles a Botox case
Elsevier launches new drug class overviews, a whistleblower accuses Abbott and Genzyme clears the way for Lemtrada.
J&J is said to be circling a Risperdal settlement, Novartis links up with UPenn to fight cancer, and Astellas puts 13 scientists out of work.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.